Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: Cytotoxic treatment during the surgical phase

Annals of Oncology

Volumn 14, Issue 10, 2003, Pages 1477-1483

  Colleoni, Marco ^a   Curigliano, G ^a   Minchella, I ^a   Peruzzotti, G ^a   Nole F ^a   Mazzarol, G ^a   Renne, G ^a   Orlando, L ^a   Rocca, A ^a   Veronesi, P ^b   Intra, M ^b   Viale, G ^a   Sandri, M T ^a   Severi, G ^b   Goldhirsch, A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Fluorouracil; Operable breast cancer; Perioperative chemotherapy

Indexed keywords

ANTIBIOTIC AGENT; ANTIEMETIC AGENT; CEFAZOLIN; CISPLATIN; CYTOTOXIC AGENT; DEXAMETHASONE; ESTROGEN RECEPTOR; FLUOROURACIL; GRANISETRON; KI 67 ANTIGEN; LOW MOLECULAR WEIGHT HEPARIN; NAVELBINE; PROGESTERONE RECEPTOR; WARFARIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG RESPONSE; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HUMAN TISSUE; LEUKOPENIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PARESTHESIA; PATIENT SELECTION; PERIOPERATIVE PERIOD; POSTOPERATIVE VOMITING; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN MANIFESTATION; THORAX PAIN; THROMBOCYTOPENIA; WOUND HEALING;

EID: 10744231683     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg411     Document Type: Article

References (32)

1. Kurebayashi J, Nukatsuka M, Fujioka A et al. Postsurgical oral administration of uracil and tegafur inhibits progression of micrometastasis of human breast cancer cells in nude mice. Clin Cancer Res 1997; 3: 653-659.
2. van Putten LM. Optimal timing of adjuvant chemotherapy in mouse models. Prog Clin Biol Res 1985; 201: 15-21.
3. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastasis. Cancer Res 1983; 43: 1488-1492.
4. Fisher B, Gunduz N, Coyle J et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49: 1996-2001.
5. Ono I, Gunji H, Suda K et al. Evaluation of cytokines in donor site wound fluid. Scand J Plast Reconstr Surg Hand Surg 1994; 28: 269-273.
6. Abramovitch R, Marikovsky M, Meir G, Neeman M. Stimulation of tumour growth by wound-derived growth factors. Br J Cancer 1999; 79: 1392-1398.
7. Clahsen PC, van de Velde CJ, Goldhirsch A et al. Overview of randomized perioperative polychemotherapy trials in women with early stage breast cancer. J Clin Oncol 1997; 15: 2526-2535.
8. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
9. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424-429.
10. Smith IE, A'Hern RP, Howell A et al. Preoperative continuous infusional ECisF (epirubicin, cisplatin and infusional 5 FU) V. Conventional AC chemotherapy for early breast cancer: a phase III multicentre randomised trial by the topic trial group. Proc Am Soc Clin Oncol 2000; 19: 320.
11. Colleoni M, Minchella I, Mazzarol G et al. Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesteron receptors. Ann Oncol 2000; 11: 1-3.
12. Nole F, Munzone E, Mandala M et al. Vinorelbine, cisplatin and continuous infusion of 5-fluorouracil (ViFuP) in metastatic breast cancer patients: a phase II study. Ann Oncol 2001; 12: 95-100.
13. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
14. Bonadonna G, Veronesi U, Brambilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-1545.
15. Mauriac L, MacGrogan G, Avril A et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 1999; 10: 47-52.
16. Nissen-Meyer R, Kjellgren K, Malmio K et al. Surgical adjuvant chemotherapy: results with one short course with cyclophosphamide after mastectomy from breast cancer. Cancer 1978; 41: 2088-2098.
17. Fisher B, Slack N, Katrych D, Wolmark N. Ten-year follow-up results of patients with carcinoma of the breast in a co-operative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gynecol Obstet 1975; 140: 528-534.
18. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989; 320: 491-496.
19. Lange PH, Hekmat K, Bosl G et al. Accelerated growth of testicular cancer after cytoreductive surgery. Cancer 1980; 15: 1498-1506.
20. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979; 39: 3861-3865.
21. Eggermont AM, Steller EP, Marquet RL et al. Local regional promotion of tumor growth after abdominal surgery is dominant over immunotherapy with interleukin-2 and lymphokine activated killer cells. Cancer Detect Prev 1988; 12: 421-429.
22. Badwe RA, Mittra I, Havaldar R. Timing of surgery during the menstrual cycle and prognosis of breast cancer. J Biosci Mar 2000; 25: 113-120.
23. Goldhirsch A, Gelber RD, Castiglione M et al. Menstrual cycle and timing of breast surgery in premenopausal node-positive breast cancer: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Ann Oncol 1997; 8: 751-756.
24. McCulloch P, Choy A, Martin L. Association between tumour angiogenesis and tumour cell shedding into effluent venous blood during breast cancer surgery. Lancet 1995; 346: 1334-1335.
25. Eisen T, Smith IE, Johnston S et al. Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. J Clin Oncol 1998; 16: 1350-1357.
26. Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412-3417.
27. Goldhirsch A, Gelber RD, Davis BW. Breast disease. In Forbes JF (ed.): Edinburgh Adjuvant Chemotherapy Trials in Breast Cancer: an Appraisal and Lessons for Patient Care Outside the Trials. Churchill Livingstone 1986; 123-138.
28. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998; 352: 930-942.
29. NSABP. The effect on primary tumor response of adding sequential taxotere to adriamycin and cyclophosphamide: preliminary results from NSABP protocol B-27. Breast Cancer Res Treat 2001; 69: 5.
30. Smith IC, Heys SD, Hutcheon AW et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
31. Bonadonna G, Zambetti M, Bumma C et al. Multimodal treatment with primary agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo cooperative group. Ann Oncol 2002; 13: 1049-1058.
32. Bondestam J, Salven P, Jaaskela-Saari H et al. Major surgery increases serum levels of vascular endothelial growth factor only temporarily. Am J Surg 2000; 179: 57-59.